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Abstract 
Purpose: Papillary early gastric carcinoma (EGC) is uncommon but shows worse prognosis in our most 
recent study in a Chinese population with unknown reasons. The aim of the present study was to 
further investigate risk factors for worse prognosis in patients with papillary adenocarcinoma, 
compared to those with tubular adenocarcinoma. 
Methods: We searched the electronic pathology databank for radical gastrectomy cases over an 8-year 
period at a single medical center in Nanjing, China, and identified consecutive 240 EGC cases that were 
classified as either papillary (n=59) or tubular (n=181) EGC tumors in accordance with the World 
Health Organization (WHO) gastric cancer diagnosis criteria. We investigated and compared 
clinicopathologic risk factors for prognosis between papillary and tubular EGC groups. All patients were 
followed up and their 5-year survival rate was compared statistically with the Kaplan-Meier method with 
a log rank test.  
Results: Compared to tubular EGCs, papillary EGCs were significantly more common in elderly 
patients, more frequently occurred in the proximal stomach with protruding/elevated growth patterns, 
submucosal invasion, and a micropapillary component. Although lymphovascular invasion (16.9%), nodal 
(13.6%) and distant (11.8%) metastases in papillary EGCs were more frequent than those (8.3%, 7.2%, 
and 3.7%, respectively) in tubular EGCs, the differences approached but did not reach statistically 
significant levels. Significant risk factors for nodal metastasis included lymphovascular invasion in both 
EGC groups, but the ulcerative pattern and submucosal invasion only in tubular EGCs. The 5-year 
survival rate was significantly worse in papillary (80.5%) than in tubular (96.8%) EGCs. 
Conclusions: Compared to tubular EGCs, papillary EGCs diagnosed with the WHO criteria in Chinese 
patients were more frequent in elderly patients, proximal stomach and showed the significantly worse 
5-year survival rate with more protruding/elevated growth patterns and the micropapillary component. 
Further studies in larger samples are urgently needed to validate these findings for precision 
individualized EGC patient management. 
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Introduction 
The World Health Organization (WHO) 
classifies gastric adenocarcinoma into 5 main types: 
tubular, papillary, mucinous, poorly cohesive, and 
mixed, in which the most common type is tubular, 
whereas papillary adenocarcinoma is uncommon [1]. 
Papillary adenocarcinoma is characterized by 
finger-like projections lined with neoplastic columnar 








with small micropapillary and tubular components in 
some tumors [1]. Both papillary and tubular 
adenocarcinomas are also grouped as “intestinal” 
(versus “diffuse”, according to the Lauren 
classification) [2] or “differentiated” (versus 
“undifferentiated”, based on the Japanese 
classification) [3] gastric carcinoma. 
Gastric carcinoma remains one of the most 
common cancers and the leading cause of cancer 
deaths worldwide [4], especially in China with over 
43% of worldwide gastric cancer cases [5]. At present, 
the only hope for improving patient survival is the 
early detection and resection of early gastric 
carcinoma (EGC), which is defined as invasive 
carcinoma in the depth up to the submucosal layer, 
regardless of the nodal status [1]. Both papillary and 
tubular adenocarcinomas at the early pT1 stage in the 
size of smaller than 2 cm without ulceration or 
lymphovascular invasion are considered to have a 
minimal or no risk for nodal metastasis on the basis of 
study results published in 2000 by Japanese 
investigators [6]; as such, EGC tumors are suitable for 
endoscopic resections, such as endoscopic 
submucosal dissection (ESD), because of minimal 
injury and safe to EGC patients, as recommended by 
both Japanese and Chinese clinical practice guidelines 
[7,8].  
In our most recent study on EGC in Chinese 
patients [9], we found surprisingly that the patients 
with papillary EGC had worse prognosis than those 
with tubular EGC; in addition, a high nodal metastatic 
rate was found in half cases of papillary EGCs with a 
small micropapillary component [9]. In fact, Japanese 
and Korean investigators have reported previously a 
considerable proportion of papillary adenocarcinoma 
cases with liver and nodal metastases and worse 
prognosis [10-13]. While those investigators follow the 
Japanese EGC diagnostic criteria in which invasion is 
not considered the most important criterion for 
carcinoma diagnosis [14], the prognosis and risk of 
nodal metastasis in papillary EGC remains unclear in 
Chinese patients, in whom EGC is diagnosed 
primarily with the WHO criteria. The purpose of this 
study was to further analyze our EGC database 
previously established at a single high-volume 
medical center in China to delineate and compare the 
prognosis and risk factors for nodal metastasis 
between papillary and tubular EGCs, which were 
diagnosed with the stringent WHO criteria [1].  
Methods and Material 
Patient Groups 
In the prospectively built pathology electronic 
databank with gastric cancer resection cases over an 
8-year period from 2005 to 2012, we found and 
retrospectively reviewed a total of 3176 pathology 
reports on radical gastrectomy and identified 
consecutive 379 EGC cases with lymphadenectomy. 
Each EGC pathology report along with all histology 
slides was retrieved and investigated. Histology types 
of EGC were confirmed or modified strictly with the 
WHO diagnostic criteria [1]. Excluded were the cases 
with synchronous or gastric stump tumors and the 
cases without slides for review or tissue blocks for 
recuts. The cases with the diagnosis of papillary or 
tubular adenocarcinoma were selected for the 
comparison study and divided into the two groups, 
respectively. The patient demographic information 
was extracted from the pathology report. Each 
endoscopic report along with all endoscopic and gross 
images of selected EGC tumors was studied for the 
information of tumor location and endoscopic tumor 
growth patterns, which were categorized in 
accordance with the Paris classification [15]. Patient 
consent to surgical resection and clinical research of 
the tumor was collected with the signature prior to the 
surgical resection. The study protocol was approved 
by the Medical Ethics Committee of the Nanjing 
Drum Tower Hospital in China. 
Pathology Investigation 
With a standard pathology tissue processing 
protocol [9], all surgical resection specimens were 
carefully evaluated for tumor location, size, shape, 
color, surface appearance, invasion depth, and 
consistency. The stomach was divided into proximal 
and distal regions, as previously described [16]. The 
proximal stomach, also known as gastric cardia, was 
defined as a narrow region of about 3 cm below the 
gastroesophageal junction grossly[16,17], and 
confirmed microscopically by histologic landmarks, 
such as the distal ends of the squamous epithelium, 
multi-layered epithelium, and deep esophageal 
glands and ducts[16]. All other parts of the stomach, 
such as corpus, antrum, and pylorus, were grouped as 
the distal stomach. The tumor maximal size was 
measured manually in the formalin-fixed specimen 
and recorded. Microscopic examination was carried 
out by at least two senior pathologists with special 
interest and experience in gastrointestinal pathology. 
The endoscopic ulcerative pattern was re-assessed by 
histologic identification of disruption of the lamina 
propria to the muscularis mucosae and beyond. 
Guided by the WHO diagnostic criteria [1], we 
classified papillary adenocarcinoma into two major 
morphologic growth patterns: 1) the conventional 
villiform pattern on well oriented sections (Figure 1), 
or as free-floating villi with a fibrovascular core or 
lamina propria, if occupied more than 50% of the 




estimated tumor volume on the same slide[10,11]; 2) 
the micropapillary pattern, featuring small 
pseudopapillary tumor clusters surrounded by empty 
lacuna spaces without a fibrovascular core (Figure 2), 
if found in over 5% of the estimated tumor volume[9]. 
In contrast, tubular adenocarcinoma demonstrated a 
more versatile growth spectrum, including tubular, 
acinar, cribriforming, anastomosing, dys-union, 
microcyst, spiky branching, and budding patterns, etc. 
In each EGC tumor, the invasion depth was 
semi-quantitatively determined on the best oriented 
tumor section and divided among 4 subgroups: 
lamina propria (M2), muscularis mucosae (M3), and 
superficial (<500 µm) (SM1) or deep (>500 µm) (SM2) 
submucosal layer. In tumors with submucosal 
invasion, lymphovascular and perineural invasion 
was also assessed. In cases with equivocal 
lymphovascular invasion on hematoxylin-eosin 
stained sections, routine immunostains for D2-40 and 
CD34 were carried out with both negative and 
positive controls in each run, as previously described 
[9]. Lymph node metastasis was evaluated with 
manual counting lymph nodes retrieved and the 
nodes with metastasis, identified on a routine 
hematoxylin-erosin stained tumor section in each 
case. The information on tumor distant metastasis was 
acquired by reviewing the patient electronic medical 




Figure 1. Representative papillary early gastric adenocarcinoma in the gastric angularis incisura with the endoscopic O-IIC growth pattern in A. By histology in B, the 
tumor shows a villiform growth feature with finger-like papillary projections and fibrovascular cores. 
 
 
Figure 2. Representative micropapillary early gastric adenocarcinoma in the gastric antrum with the endoscopic O-IIA/O-IIC grow patterns in A. Microscopically, the 
tumor shows micropapillary features without fibrovascular cores but demonstrates empty spaces surrounding each tumor micropapilae. 
 





Differences in clinicopathology, endoscopy, and 
survival between papillary and tubular EGC groups 
were assessed with the Chi-square and Student’s t 
tests. Patient survival was calculated from the month 
of EGC diagnosis to the month of the last follow-up if 
alive, or death of all causes. Survival rates were 
estimated with the Kaplan-Meier method with a log 
rank test. Univariate and multivariate analyses were 
carried out with the logistic proportional hazards 
model to determine independent risk factors of nodal 
metastasis. The Statistical Package for the Social 
Sciences (SPSS, version 19.0, Chicago, IL, the United 
States of America) was employed for all statistical 
analyses. P values smaller than 0.05 were considered 
as statistically significant. 
Results 
Among 379 EGC cases, 240 were qualified for the 
study and divided into the papillary (n = 59, 24.6%) 
and tubular (n = 181, 75.4%) groups.  
Comparison in Clinical, Endoscopic, and 
Pathologic Characteristics  
As shown in Table 1, there were no statistically 
significant differences in gender and tumor size 
between the two EGC groups. However, patients in 
the papillary group were significantly older for the 
age over 61-year category (78%), compared to those in 
the tubular (58.6%) group (p = 0.007). Similarly, the 
papillary group demonstrated significantly more 
frequent proximal gastric location (55.9% vs. 28.7%) (p 
< 0.001), protruding/elevated (OI + OIIa) endoscopic 
growth patterns (66.1% versus 39.2%)(p < 0.001), 
submucosal invasion (64.4% versus 43.6%)(p < 0.05), 
and the micropapillary growth pattern (6.8% versus 
0)(p < 0.003). Lymphovascular invasion was more 
than twice as common as in the papillary (16.9%) than 
in the tubular (8.3%) group, and the difference almost 
reached a statistically significant level (p = 0.059). 
Likewise, although nodal metastasis was also more 
frequently discovered in the papillary (13.6%) than in 
the tubular (7.2%) groups, the difference was not 
statistically significant (p = 0.132). Similarly, distant 
metastasis was over 3-fold as common in the papillary 
(11.8%) as in the tubular (3.7%) group, the difference 
did not reach a statistically significant level (p = 
0.067). Importantly, the overall 5-year survival rate 
was significantly worse in the papillary (80.5%) 




Figure 3. Comparison of the post-resection prognosis exhibits a statistically 
significant worse survival for the papillary early gastric adenocarcinoma group, 
compared to that of the tubular early gastric adenocarcinoma group. 
Table 1. Comparison of clinical, endoscopic, and pathologic 
features between papillary and tubular early adenocarcinoma. 
Feature Papillary (n=59) (%) Tubular (n=181) 
(%) 
P 
Age (years)  65.9 ± 6.9 62.4 ± 10.1  
≤ 60 13 (22.0) 75 (41.4) 0.007 
≥ 61 46 (78.0) 106 (58.6)  
Gender    
Male 43 (72.9) 130 (71.8) 0.875 
Female 16 (27.1) 51 (28.2)  
Tumor location    
Proximal (Cardia) 33 (55.9) 52 (28.7) <0.001 
Distal (non-cardia) 26 (44.1) 129 (71.3)  
Tumor size (cm)    
< 2 35 (59.3) 117 (64.6) 0.230 
≥ 2 24 (40.7) 64 (35.4)  
Endoscopic gross type   <0.001 
O-I 22 (37.3) 13 (7.2)  
O-IIa 17 (28.8) 58 (32.0)  
O-IIb 4 (6.8) 4 (2.2)  
O-IIc 4 (6.8) 38 (21.0)  
O-III 12 (20.3) 68 (37.6)  
Tumor invasion depth   0.048 
M2 9 (15.3) 49 (27.1)  
M3 12 (20.3) 53 (29.3)  
SM1 21 (35.6) 46 (25.4)  
SM2 17 (28.8) 33 (18.2)  
Micropapillary pattern    
Present 4 (6.8) 0 (0) 0.003 
Absent 55 (93.2) 181 (100)  
Lymphovascular invasion    
Present 10 (16.9) 15 (8.3) 0.059 
Absent 49 (83.1) 166 (91.7)  
Perineural invasion    
Present 0 2 (1.1) >0.999 
Absent 59 (100) 179 (98.9)  
Distant Metastasis (n=51) (n=162)  
Present 6 (11.8) 6 (3.7) 0.067 
Absent 45 (88.2) 156 (96.3)  
Lymph Node Metastasis    
Present 8 (13.6) 13 (7.2) 0.132 
Absent 51 (86.4) 168 (92.8)  
5-year survival rate 80.50% 96.8% 0.016 
Note: NS: Not significant. 




Differences in Risk Factors of Lymph Node 
Metastasis 
By univariate analysis, advanced age, male 
gender, tumor proximal gastric location, and tumor 
size over 2 cm were not statistically significant risk 
factors for nodal metastasis in either the papillary or 
tubular EGC group (Table 2). The risk of nodal 
metastasis for the endoscopic ulcerative pattern was 
significant only in the tubular (p < 0.05), but not in the 
papillary group. Similarly, submucosal invasion was 
a significant risk factor of nodal metastasis also only 
in the tubular (p < 0.05), but not in the papillary 
group. In contrast, the risk of nodal metastasis in cases 
with the micropapillary pattern approached, but did 
not reach, the statistically significant level in the 
papillary (p = 0.054), but not in the tubular group. As 
previously indicated [9], lymphovascular, but not 
perineural, invasion exhibited a significant risk of 
over 35-fold in papillary and over 36-fold in tubular 
groups for nodal metastasis (p < 0.001). 
Independent Risk Factors of Lymph Node 
Metastasis 
Table 3 showed the results of multivariate 
analysis of 3 key risk factors related to the risk of 
lymph node metastasis in papillary and tubular 
EGCs. Neither the advanced age nor the 
micropapillary growth pattern was found to be a 
statistically significant risk factor for nodal metastasis. 
In contrast, lymphovascular invasion showed over 
31-fold risk of nodal metastasis in papillary EGCs, 
higher than that (26.5-fold) in tubular EGCs. 
Table 2. Risk factors of lymph node metastasis between patients with early papillary or tubular adenocarcinoma Risk factors of lymph 
node metastasis between patients with early papillary or tubular adenocarcinoma. 
Feature Papillary (n= 59 ) Tubular (n = 181 ) 
 OR (95% CI)* P OR (95% CI) P 
Age (year)      
≤ 60 2.46 (0.50 - 12.06) 0.267 1.72 (0.55 - 5.33) 0.350 
≥ 61 Ref  Ref  
Gender     
Male Ref  Ref  
Female 0.88 (0.16 - 4.89) 0.885 2.34 (0.75 - 7.35) 0.144 
Tumor location     
Proximal (Cardia) Ref    
Distal (non-cardia) 7.18E8 (0 - ) 0.998 1.81E8 (0 - ) 0.997 
Tumor size (cm)     
< 2 Ref  Ref  
≥ 2 1.55 (0.35 - 6.92) 0.566 2.27 (0.73-7.08) 0.157 
Endoscopic gross type     
O-I/IIa/IIb/IIc Ref  Ref  
O-III (ulcerated) 0.52 (0.06 - 4.68) 0.559 4.16 (1.23-14.08) 0.022 
Tumor invasion depth     
M2 and M3 Ref  Ref  
SM1 and SM2 4.31E8 (0-) 0.998 18.09 (2.30-142.39) 0.006 
Micropapillary pattern     
Present 8.17 (0.97-69.10) 0.054 2.21 (0.68 - 7.17) 0.185 
Absent Ref  Ref  
Lymphovascular invasion     
Present 35.25 (5.28-235.25) <0.001 36.80 (9.55-141.88) <0.001 
Absent Ref  Ref  
* OR: Odds Ratio; CI, confidence interval; Ref: reference. 
Table 3. Intendant risk factors of lymph node metastasis of early papillary versus tubular adenocarcinoma. 
Feature Papillary Tubular 
OR (95% CI)* P OR (95% CI) P 
Tumor invasion depth     
M2 and M3 -  Ref  
SM1 and SM2 -  6.43 (0.72-57.37) 0.096 
Endoscopic gross type     
O-I/IIa/IIb/IIc -  Ref  
O-III -  3.93 (0.83-18.70) 0.086 
Micropapillary pattern     
Present 4.79 (0.26-88.68) 0.293 -  
Absent Ref  -  
Lymphovascular invasion     
Present 31.11 (4.49-215.38) <0.001 26.45 (5.58-125.43) <0.001 
Absent Ref  Ref  
* OR: Odds Ratio; CI, confidence interval; Ref: reference. 





In this comparison study, our data illustrate 
significantly worse prognosis in papillary EGC with a 
significantly lower 5-year survival rate of 80.5%, 
compared to 96.8% in tubular EGC. This surprising 
finding may be related to the more frequent presence 
of high risk factors for worse prognosis in papillary 
EGC. In our cohort, papillary EGCs, compared to 
tubular EGCs, show significantly deeper invasion into 
the submucosal layer, more frequent association with 
a micropapillary component, and probably more 
frequent lymphovascular invasion, although the p 
value for lymphovascular invasion was 0.059. These 
results are parallel to those of the previous similar 
studies on papillary EGC from Japan [18,19] and 
Korea [13], in which submucosal invasion was 
reported to be over 20% [13], and lymphovascular 
invasion was found in over 28% in Korean patients 
[13] and over 70% in Japanese patients [18]. 
Importantly, the nodal metastasis rate is alarmingly 
high and discovered in 13.6% of the current cohort 
and over 18% in a Korean study and 18.2% - 29.2% in 
two Japanese studies [18,19], which is significantly 
higher than that of non-papillary EGCs [13,19], 
including tubular EGCs as shown in this report. Those 
results raise a serious legitimate concern on 
indiscriminate use of endoscopic resection, such as 
ESD [7,8], for papillary EGC because nodal metastasis 
is a contraindication for endoscopic resection of EGC.  
Although both papillary and tubular EGC 
tumors are believed to be similar in prognosis and risk 
of nodal metastasis [6], the recent investigations from 
others and ours show the results otherwise [9,13,18]. 
We demonstrated several significant differences in the 
present comparison study between these two groups 
of EGC in prognosis-associated risk factors, such as 
significantly older patient age, more frequent 
proximal gastric location, and more common 
association with a micropapillary component, in 
addition to deeper invasion and higher frequency of 
lymphovascular, nodal, and distant metastases, as 
aforementioned. In EGC, lymphovascular invasion 
has been confirmed repeatedly as the most important 
risk factor for nodal metastasis [9,20,21]. According to 
Sekiguchi et al, the independent risk factors for 
lymphovascular invasion include large tumor size, 
submucosal invasion, undifferentiated 
adenocarcinoma, and papillary EGC that has over 
8-fold risk, even for intramucosal EGC (60%, 3/5) [12]. 
Distant metastasis is also more common in papillary 
than in tubular EGCs, as reported previously for 
papillary gastric cancer [10], although the difference 
in the current study did not reach a statistically 
significant level because of the small sample size. 
Given more aggressive pathobiologic behavior and 
higher risk of nodal and distant metastases than 
tubular EGCs, papillary EGCs need to be treated 
differently and individually [13,18].  
Despite scarce published studies on papillary 
EGC, the available evidence, primarily from Japan 
and Korea, exhibits significantly different molecular 
pathogenesis mechanisms between papillary and 
tubular EGC tumors. For instance, compared to 
tubular EGCs with a high expression of intestine-type 
molecular markers such as MUC2 and CDX2, 
papillary EGCs show a distinctly higher expression of 
gastric mucin such as MUC5AC and MUC6 [18,22]. 
The gastric mucin phenotype in papillary EGCs has 
been reported to be significantly correlated to 
lymphatic invasion, nodal metastasis, and abnormal 
E-cadherin gene expression [18]. Most recently, 
Sugimoto et al discovered a significantly higher 
frequency of microsatellite instability in half (9/18) 
papillary EGC tumors, compared to tubular EGCs 
[22]. Since both KRAS and BRAF gene mutations are 
rare in EGC, the microsatellite instability is suspected 
to be a major precursor lesion in EGC [22]. 
Apparently, further studies in larger samples from 
different ethnic populations are required to validate 
the findings that are important for patient 
management because of different prognosis and 
responses to 5-FU-based chemotherapy in gastric 
carcinoma with high microsatellite instability [23,24].  
The limitations of this study are several. 1).The 
retrospective study design inherits unavoidable 
selection bias, although consecutive cases were used 
in this study to minimize that shortcoming. 2). We 
followed the WHO guideline to select EGC tumors 
with a major papillary growth pattern in over 50% of 
the tumor volume for the comparison study. We 
excluded some cases with a minor papillary pattern in 
a mixed tumor, which may have different profiles 
affecting prognosis and risk of metastasis. 3) The 
sample size in the current study is small with 
unsatisfactory statistical results in p values that 
approach the threshold for several risk factors. To 
validate the study results, we are currently 
conducting large-scale multicenter studies with the 
goal to illustrate accurately clinicopathology and 
prognosis of papillary EGCs in comparison with other 
types of EGCs for a better individualized EGC patient 
treatment strategy.  
Conclusions 
Papillary EGCs are uncommon but has higher 
propensity in elderly patients, proximal gastric 
location, elevated growth pattern, deeper invasion, 
higher lymphovascular invasion frequency, more 
nodal and distant metastases, and worse overall 




5-year survival rates, compared with tubular EGCs 
[9,13,18,20]. Because papillary EGCs can be easily 
identified by routine pathology evaluation, its high 
risk characteristics for worse prognosis should be 
used to guide clinical practice. Since most published 
studies on papillary EGCs, including our own, are 
based on single-center experience with small samples, 
it is urgent to perform systematic investigation of 
papillary EGCs in multicenter studies for an optimal 
clinical management of EGC patients.  
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